AI for Drug Discovery Market To Touch The Value Of About USD 12,135 Million By 2027: Facts and Factors

According to the report, the global AI for drug discovery market was valued at approximately USD 591 million in 2018 and is expected to reach a value of around USD 12,135 million by 2027, at a CAGR of around 39.8 % between 2019 and 2027.

AI for drug discovery is a technique that makes use of tools such as deep learning and machine learning that helps in adding value to the decision-making methods of drug discovery. The massive occurrence of rare ailments and escalating need for personalized medicine has prompted the demand for AI for drug discovery market.

Request Free Sample Copy of Research Report @ https://www.fnfresearch.com/sample/ai-for-drug-discovery-market-by-drug-type

Huge demand for genetic data analysis to spur the market growth

With giant pharma firms focusing on genetic data interpretation of patients, the market for AI for drug discovery is likely to gain traction over the forecast timeline. Understanding of the patient’s genetic profile assists in providing apt medicines as well as medical treatment for the patients. Moreover, the computational approaches of machine learning help in analyzing genetic data of the patient and propose new drug and therapies.

Additionally, clinical practice based on the machine learning tools has generated huge demand for personalized medicines as well as drug discoveries. Furthermore, the healthcare and pharmaceutical sectors have been benefitted significantly from the use of machine learning computational methods in clinical practice. The machine learning tools are used for determining the body resistance to a particular type of drugs as well as resistance to combined drug therapies based on genotype interpretation.

Download a Free Report PDF Brochure: https://www.fnfresearch.com/sample/ai-for-drug-discovery-market-by-drug-type

Small molecule segment dominates the drug type segment

The growth of the small molecule segment can be attributed to its notable contribution towards a large number of new drug application approvals over the past few years. Apart from this, the segment has also contributed significantly towards new molecular entities over the last few years. The small molecule segment is projected to register the highest growth rate of nearly 40.7% during the forecast timeframe.

Machine learning to contribute majorly towards the overall market earnings

Machine learning segment, which contributed nearly 50% towards overall market share in 2018, is expected to make sizable contributions towards the global market revenue even during the forecast timespan. The growth of this segment is due to the ability of the machine learning tools in assisting the researchers in using new computational algorithms for developing or designing novel drugs. Machine learning can also be used to create software for testing medicines as well as combinational therapies.

Request Customized Copy of Report @ https://www.fnfresearch.com/customization/ai-for-drug-discovery-market-by-drug-type

(We customize your report according to your research need. Ask our sales team for report customization.)

Pharmaceutical companies sector to lead the end user segment

The pharmaceutical companies segment contributed around 40% of the overall market share in 2018 and is likely to register major market revenue share during the forecast period. The growth can be attributed to pharma giants focusing on using the machine learning tools to derive the exact information from the clinical data output obtained after performing clinical drug trials.

North America to lead the overall market growth in terms of value

The growth of the market in North America can be credited to the high acceptance of new technologies, the presence of major industry participants, and large scale investments in drug discovery research activities.

The major participants involved in the AI for drug discovery market include Recursion Pharmaceuticals, AstraZeneca, Astrocyte Pharmaceuticals, Inc., NeuroVive Pharmaceutical AB, twoXAR Incorporated, Biogen, Bionure Farma, S.L., BIOAGE, Genervon Biopharmaceuticals, LLC., Hoffmann-La Roche Ltd., Neuren Pharmaceuticals, Atomwise, Insilico Medicine, Silicon Therapeutics, Cloud Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Teva Pharmaceutical Industries Ltd., BenevolentAI, Exscientia, Numerate, Envisagenics, Inc., and Accutar Biotech.

More Report Details: https://www.fnfresearch.com/ai-for-drug-discovery-market-by-drug-type

This report segments the AI for drug discovery market as follows:

Global AI for Drug Discovery Market: By Drug Type Segment Analysis

Small Molecule
Large Molecule

Global AI for Drug Discovery Market: By Technology Segment Analysis

Deep Learning
Machine Learning
Others

Global AI for Drug Discovery Market: By Therapeutic Area Segment Analysis

Metabolic Diseases
Immuno-Oncology
Neurodegenerative Diseases
Cardiovascular Diseases
Oncology
Others

Global AI for Drug Discovery Market: By End User Segment Analysis

Pharmaceutical Companies
Academic & Research Institutes
Biopharmaceutical Companies
Others

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: sales@fnfresearch.com
Web: https://www.fnfresearch.com

About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

This release was published on openPR.